$PRCT

PROCEPT BioRobotics Corp (PRCT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On September 23, 2026, PROCEPT BioRobotics Corporation (the “Company”) entered into a Third Amendment to Loan and Security Agreement (the “Third Amendment”) with Canadian Imperial Bank of Commerce (“CIBC”), which amends the Loa

Wood Larry L (President, CEO) purchased 23,900 indirectly-held shares of PROCEPT BioRobotics Corp (PRCT) at $20.85 ($0.50M total) on 2026-08-07.

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

PROCEPT BioRobotics (Nasdaq: PRCT) said it will release second-quarter 2026 financial results after market close on Aug. 4, 2026, and hold a conference call at 4:30 p.m. ET. The company noted its AQUABEAM and HYDROS robotic systems used for Aquablation therapy in urology.

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.

PROCEPT BioRobotics Corp (PRCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. prct-20260609 0001588978 false 0001588978 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

PROCEPT BioRobotics EVP and Chief Technology Officer Barry L. Templin has filed an initial ownership report (Form 3) detailing his equity stake and stock options in the company. The report shows that Templin directly holds 69,311 shares of Common Stock and indirectly holds 56,457 shares through the Templin Trust. Additionally, it lists various stock options with different exercise prices and expiration dates, which are subject to time-vesting schedules tied to his continued service.

PROCEPT BioRobotics reported a 20% increase in Q1 2026 revenue to $83.1 million, driven by higher system sales, consumables, and services, especially in the United States. Despite an improved gross margin of 65%, the company's net loss widened to $31.6 million due to increased spending on research, sales, and administration to support growth initiatives. As of March 31, 2026, the company had $245.6 million in cash and cash equivalents and an installed base of 971 robotic systems globally.

Procept Biorobotics (PRCT) exceeded Q1 2026 EPS and revenue forecasts, reporting $0.56 EPS against an anticipated -$0.56, and $83.13 million in revenue. Despite strong financial performance, which included a 20% year-over-year revenue increase and a 65% gross margin, the stock declined by 5.73%, reflecting investor concerns over future profitability due to projected negative EPS. The company is focusing on operational excellence, commercial discipline, and international expansion, with executives expressing confidence in long-term growth driven by strategic realignments and product innovations.